Repurposing of the Fasciolicide Triclabendazole to Treat Infections Caused by
bacterial pathogens
bioluminescence
multidrug resistance
polymyxin B
sepsis
triclabendazole
Journal
Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893
Informations de publication
Date de publication:
10 Aug 2021
10 Aug 2021
Historique:
received:
30
06
2021
revised:
02
08
2021
accepted:
03
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
One approach to combat the increasing incidence of multidrug-resistant (MDR) bacterial pathogens involves repurposing existing compounds with known safety and development pathways as new antibacterial classes with potentially novel mechanisms of action. Here, triclabendazole (TCBZ), a drug originally developed to treat
Identifiants
pubmed: 34442776
pii: microorganisms9081697
doi: 10.3390/microorganisms9081697
pmc: PMC8398527
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Australian Research Council
ID : LP130100736
Références
Curr Opin Microbiol. 2017 Oct;39:106-112
pubmed: 29154024
Ann Clin Microbiol Antimicrob. 2020 Nov 3;19(1):50
pubmed: 33143710
J Health Econ. 2016 May;47:20-33
pubmed: 26928437
Nat Rev Drug Discov. 2015 Dec;14(12):821-32
pubmed: 26493767
J Med Chem. 1975 Nov;18(11):1164-6
pubmed: 1177265
Curr Pharm Des. 2015;21(28):4106-11
pubmed: 25961308
Int J Antimicrob Agents. 2019 Apr;53(4):371-382
pubmed: 30472287
Antimicrob Agents Chemother. 2017 May 24;61(6):
pubmed: 28416543
Antimicrob Agents Chemother. 2003 Jul;47(7):2283-92
pubmed: 12821480
AAPS J. 2012 Dec;14(4):759-63
pubmed: 22826034
Front Med (Lausanne). 2019 Apr 16;6:74
pubmed: 31041313
PLoS One. 2018 Jul 16;13(7):e0200195
pubmed: 30011298
Br J Pharmacol. 2018 Jan;175(2):168-180
pubmed: 28369768
J Pharm Pharmacol. 2015 Feb;67(2):264-73
pubmed: 25495516
Biosci Rep. 2019 Apr 12;39(4):
pubmed: 30910848
Front Microbiol. 2015 Apr 09;6:282
pubmed: 25914685
Br J Pharmacol. 2018 Jan;175(2):181-191
pubmed: 28685814
Phytomedicine. 2012 Nov 15;19(14):1288-97
pubmed: 23146422
PLoS One. 2017 Sep 5;12(9):e0183457
pubmed: 28873428
Nat Rev Drug Discov. 2019 Jan;18(1):41-58
pubmed: 30310233
J Antibiot (Tokyo). 2020 Jun;73(6):392-409
pubmed: 32132676
Antimicrob Agents Chemother. 2005 Oct;49(10):4166-73
pubmed: 16189094
Antibiotics (Basel). 2019 May 04;8(2):
pubmed: 31060222
Front Microbiol. 2019 Apr 25;10:837
pubmed: 31105656
Essays Biochem. 2017 Mar 3;61(1):115-125
pubmed: 28258235
Trans R Soc Trop Med Hyg. 2019 Dec 1;113(12):797-804
pubmed: 31638149
Pharm World Sci. 2007 Jun;29(3):190-8
pubmed: 17265093
Nat Med. 2017 Apr 7;23(4):405-408
pubmed: 28388612
Trends Parasitol. 2016 Jun;32(6):458-469
pubmed: 27049013
Trends Microbiol. 2016 Nov;24(11):862-871
pubmed: 27430191
Front Microbiol. 2020 Aug 04;11:1556
pubmed: 32849325
Br J Clin Pharmacol. 1998 Jun;45(6):601-4
pubmed: 9663817
Nat Med. 2014 Jun;20(6):590-1
pubmed: 24901567
PLoS One. 2011;6(12):e28177
pubmed: 22162759
J Innate Immun. 2018;10(5-6):432-441
pubmed: 29642066
ACS Infect Dis. 2015;1(11):512-522
pubmed: 26925460
ACS Infect Dis. 2015 Nov 13;1(11):568-575
pubmed: 27525307